home / stock / nvsef / nvsef quote
Last: | $106.90 |
---|---|
Change Percent: | 0.23% |
Open: | $103.76 |
Close: | $106.90 |
High: | $106.9 |
Low: | $103.76 |
Volume: | 4,206 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$106.9 | $103.76 | $106.9 | $106.9 | $103.76 | 4,206 | 07-02-2024 |
$104 | $0 | $104 | $0 | $0 | 5 | 07-01-2024 |
$104 | $104 | $104 | $104 | $104 | 100 | 06-28-2024 |
$102.69 | $0 | $102.69 | $0 | $0 | 10 | 06-27-2024 |
$102.69 | $106.55 | $102.69 | $106.55 | $102.69 | 17,848 | 06-26-2024 |
$106.51 | $0 | $106.51 | $0 | $0 | 5,472 | 06-25-2024 |
$106.51 | $106.1 | $106.51 | $107.0849 | $106 | 2,109 | 06-24-2024 |
$102.43 | $0 | $102.43 | $0 | $0 | 60 | 06-21-2024 |
$102.43 | $108.5 | $102.43 | $108.5 | $102.43 | 5,320 | 06-20-2024 |
$104.085 | $103 | $104.085 | $104.4775 | $103 | 21,172 | 06-17-2024 |
$101.29 | $0 | $101.29 | $0 | $0 | 434 | 06-14-2024 |
$101.29 | $0 | $101.29 | $0 | $0 | 4 | 06-13-2024 |
$101.29 | $101.29 | $101.29 | $101.29 | $101.29 | 481 | 06-12-2024 |
$102 | $0 | $102 | $0 | $0 | 12,501 | 06-11-2024 |
$102 | $0 | $102 | $0 | $0 | 10 | 06-10-2024 |
$102 | $0 | $102 | $0 | $0 | 15,010 | 06-07-2024 |
$102 | $0 | $102 | $0 | $0 | 10,030 | 06-06-2024 |
$102 | $102 | $102 | $102 | $102 | 23,017 | 06-05-2024 |
$102 | $100 | $102 | $105.035 | $100 | 3,674 | 06-04-2024 |
$100 | $100 | $100 | $100 | $100 | 8,085 | 06-03-2024 |
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
Novartis Ag Basel Akt Website:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...